1236764-10-5

Upstream product

• 350-46-9 4-Fluoronitrobenzene 
• 1236764-11-6 1-nitro-4-(3,3,3-trifluoropropoxy)benzene 

Downstream Products

• 1236764-95-6 2-thioxo-3-[4-(3,3,3-trifluoropropoxy)phenyl]-1,2,3,7-tetrahydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 
• 1236764-58-1 2-thioxo-3-[4-(3,3,3-trifluoropropoxy)phenyl]-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-one 

Relevant academic research and scientific papers

SPIRO-CONDENSED CYCLOHEXANE DERIVATIVES AS HSL INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions as HSL inhibitors for the treatment of diabetes, wherein R1,R2, R3, Ca and Cb have the significance given in claim 1.

NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES

The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof. The are useful as HSL inhibitors and may, for example, be used in treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, and obesity.

Fused ring compound and use thereof

The present invention provides a compound represented by the formula: wherein the symbols are as described in the specification, or a salt thereof, which is useful for preventing/treating eicosanoid-associated diseases such as atherosclerosis, diabetes, obesity, atherothrombosis, asthma, fever, pain, cancer, rheumatism, osteoarthritis and atopic dermatitis, and which has an excellent pharmacological action, physicochemical properties, etc.

AZACYCLIC SPIRODERIVATIVES AS HSL INHIBITORS

Compounds of formula (I) as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein n, m, A, R1 and R2 have the significance given in claim 1. The compounds are useful as HSL inhibitors for the treatment of diabetes dyslipidemia, atherosclerosis and obesity.